Skip to main content
Equibles
ABUS logo

ABUS · Arbutus Biopharma Corp · Debt

Track ABUS — free

Use ABUS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ABUS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.27 -0.02 (-0.48%) Q3 2024 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$856.68M
Shares
197.85M
Volume · Oct 28 1.34M Avg daily vol (3M) 4.83M

Debt Profile

Completed filing coverage through Mar 23, 2026

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Current operating lease liabilities 2026-06-30 USD 514,000 10-Q filed 2026-08-12
Long-term debt, including current maturities 2026-06-30 USD 0 10-Q filed 2026-08-12
Noncurrent operating lease liabilities 2026-06-30 USD 0 10-Q filed 2026-08-12
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Key facts CIK 1447028 CUSIP 03879J100 13F (30d) 25 filings 25 filers Visit website Investor relations